We are live on ! Find out more
TPST icon

Tempest Therapeutics
TPST

38 hedge funds and large institutions have $90.7M invested in Tempest Therapeutics in 2019 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 12 increasing their positions, 4 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 4

100% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 8

27% more funds holding

Funds holding: 30 → 38 (+8)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

13% less capital invested

Capital invested by funds: $104M → $90.7M (-$13.6M)

Holders
38
Holders Change
+8
Holders Change %
+26.67%
% of All Funds
0.83%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
16
Increased
12
Reduced
4
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$6.68M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$1.92M
3
State Street
State Street
Massachusetts
+$1.76M
4
IBT
International Biotechnology Trust
United Kingdom
+$1.75M
5
Renaissance Technologies
Renaissance Technologies
New York
+$1.58M

Top Sellers

Rank Fund Capital Flow
1
PM
Prosight Management
Texas
-$2.97M
2
ASP
Adams Street Partners
Illinois
-$756K
3
Millennium Management
Millennium Management
New York
-$749K
4
TEE
Tibra Equities Europe
United Kingdom
-$303K
5
WVP
Worth Venture Partners
New Jersey
-$276K
Name Holding Trade Value Shares
Change 		Change in
Stake
New York State Common Retirement Fund
26
New York State Common Retirement Fund
New York
$111K +$144K +49 New
Bank of America
27
Bank of America
North Carolina
$81K +$103K +35 New
Barclays
28
Barclays
United Kingdom
$70K +$67.7K +23 +288%
AIG
29
American International Group
New York
$69K +$91.2K +31 New
Citigroup
30
Citigroup
New York
$30K -$53K -18 -58%
CSS
31
Cubist Systematic Strategies
Connecticut
$30K +$26.5K +9 +225%
JP Morgan Chase
32
JP Morgan Chase
New York
$29K +$29.4K +10 +333%
SO
33
STRS Ohio
Ohio
$28K +$38.3K +13 New
UBS Group
34
UBS Group
Switzerland
$25K +$32.4K +11 New
Legal & General Group
35
Legal & General Group
United Kingdom
$18K +$23.5K +8 New
AIP
36
Ameritas Investment Partners
Nebraska
$10K +$11.8K +4 New
Morgan Stanley
37
Morgan Stanley
New York
$6K -$38.3K -13 -81%
TRCT
38
Tower Research Capital (TRC)
New York
$4K +$5.89K +2 New
Bank of Montreal
39
Bank of Montreal
Ontario, Canada
$1K – – –
BWM
40
Baystate Wealth Management
Massachusetts
$1K – – –
TCOV
41
Trust Company of Vermont
Vermont
$1K – – –
BNP Paribas Financial Markets
42
BNP Paribas Financial Markets
France
$266 – – –
RE
43
RBC Europe
United Kingdom
$69 – – –
Millennium Management
44
Millennium Management
New York
– -$749K -256 Closed
TEE
45
Tibra Equities Europe
United Kingdom
– -$303K -104 Closed
WVP
46
Worth Venture Partners
New Jersey
– -$276K -94 Closed
PC
47
PA Capital
Virginia
– -$229K -78 Closed
FM
48
Fondren Management
Texas
– -$217K -74 Closed
Goldman Sachs
49
Goldman Sachs
New York
– -$215K -73 Closed
LC
50
Lindbrook Capital
California
– -$15K -5 Closed
1
2
3

TPST Hedge Fund Activity: Q2 2019 in Review

38 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q2 2019, worth a combined $90.7M — down 13% from $104M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new TPST positions and 8 closed out — a net gain of 8 holders — while 12 added to existing stakes and 4 trimmed.

The largest buyer was BlackRock, adding an estimated $6.68M. The largest seller was Prosight Management, cutting an estimated $2.97M.

  • 38 institutional investors held Tempest Therapeutics (TPST) as of Q2 2019, up from 30 in Q1 2019.
  • Funds reported $90.7M of Tempest Therapeutics stock for Q2 2019, down 13% quarter-over-quarter.
  • 16 funds opened new Tempest Therapeutics positions in Q2 2019 and 8 closed out, a net change of +8 holders.
  • The largest Tempest Therapeutics buyer in Q2 2019 was BlackRock, an estimated $6.68M added.
  • The largest Tempest Therapeutics seller in Q2 2019 was Prosight Management, an estimated $2.97M sold.

Based on aggregated 13F filings for Q2 2019.